PS Ratio: 24.15

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/S ratio high or low?

The P/S ratio of 24.15 is 379% above its estimated 5-year average of 5.05, near the high end of its estimated 5-year range (2.22–30.99).

As of 2026-09-09T20:00:01.000Z. 211.78% above its estimated 12-month average of 7.75.

MRNA PS Ratio Metrics

P/S vs. estimated history

At 24.15, P/S is near its estimated 8-year median — higher than 63% of readings in its estimated 8-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

Sales Valuation

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio FAQ

What is the P/S ratio for Moderna, Inc. (MRNA)?

The P/S ratio for MRNA stock is 24.15.

Is Moderna, Inc.'s P/S ratio high or low?

The P/S ratio of 24.15 is 379% above its estimated 5-year average of 5.05, near the high end of its estimated 5-year range (2.22–30.99).

What is the estimated TTM average P/S ratio for Moderna, Inc. (MRNA)?

The estimated TTM average P/S ratio for MRNA stock is 7.75.

What is the estimated 3Y average P/S ratio for Moderna, Inc. (MRNA)?

The estimated 3Y average P/S ratio for MRNA stock is 5.70.

What is the estimated 5Y average P/S ratio for Moderna, Inc. (MRNA)?

The estimated 5Y average P/S ratio for MRNA stock is 5.05.

Showing the most recent 260 of 1,948 data points. The chart above shows the full history.

Related Metrics